title: NADP and NAD utilization in Haemophilus influenzae.
abstract: Exogenous NAD utilization or pyridine nucleotide cycle metabolism is used by many bacteria to maintain NAD turnover and to limit energy-dependent de novo NAD synthesis. The genus Haemophilus includes several important pathogenic bacterial species that require NAD as an essential growth factor. The molecular mechanisms of NAD uptake and processing are understood only in part for Haemophilus. In this report, we present data showing that the outer membrane lipoprotein e(P4), encoded by the hel gene, and an exported 5'-nucleotidase (HI0206), assigned as nadN, are necessary for NAD and NADP utilization. Lipoprotein e(P4) is characterized as an acid phosphatase that uses NADP as substrate. Its phosphatase activity is inhibited by compounds such as adenosine or NMN. The nadN gene product was characterized as an NAD-nucleotidase, responsible for the hydrolysis of NAD. H. influenzae hel and nadN mutants had defined growth deficiencies. For growth, the uptake and processing of the essential cofactors NADP and NAD required e(P4) and 5'-nucleotidase. In addition, adenosine was identified as a potent growth inhibitor of wild-type H. influenzae strains, when NADP was used as the sole source of nicotinamide-ribosyl.
authors.affiliation: Zentrum für Infektionsforschung, Universität Würzburg, Röntgenring 11, 97070 Würzburg, Germany. joachim.reidl@mail.uni-wuerzburg.de
authors.forename: J
authors.initials: J
authors.lastname: Reidl
authors.forename: S
authors.initials: S
authors.lastname: Schlör
authors.forename: A
authors.initials: A
authors.lastname: Kraiss
authors.forename: J
authors.initials: J
authors.lastname: Schmidt-Brauns
authors.forename: G
authors.initials: G
authors.lastname: Kemmer
authors.forename: E
authors.initials: E
authors.lastname: Soleva
mesh_terms: D000241:Adenosine / Q000494:pharmacology; D001425:Bacterial Outer Membrane Proteins / Q000235:genetics / Q000378:metabolism; D002455:Cell Division / Q000187:drug effects / Q000235:genetics; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004950:Esterases; D006193:Haemophilus influenzae / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D008074:Lipoproteins / Q000235:genetics / Q000378:metabolism; D009154:Mutation; D009243:NAD / Q000378:metabolism* / Q000494:pharmacology; D009249:NADP / Q000378:metabolism* / Q000494:pharmacology; D009537:Nicotinamide Mononucleotide / Q000494:pharmacology; D009708:Nucleotidases / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D001425:Bacterial Outer Membrane Proteins; D004791:Enzyme Inhibitors; D008074:Lipoproteins; C098614:e(P4) lipoprotein, Haemophilus influenzae; D009243:NAD; D009537:Nicotinamide Mononucleotide; D009249:NADP; D004950:Esterases; C045660:NADP phosphatase; D009708:Nucleotidases; C030287:nucleotidase; D000241:Adenosine